Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation

Biomedicine and Pharmacotherapy

Volumn 61, Issue 2-3, 2007, Pages 154-159

  Shirakawa, Ibuki ^a   Sata, Masataka ^a   Saiura, Akio ^a   Kaneda, Yukari ^a   Yashiro, Hisako ^a   Hirata, Yasunobu ^a   Makuuchi, Masatoshi ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Arteriosclerosis; Statin; Transplantation

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; GENE EXPRESSION REGULATION; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED DBA; PYRROLES; TRANSFORMING GROWTH FACTOR BETA; TUNICA INTIMA; VASCULAR DISEASES;

EID: 34147174373     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.09.017     Document Type: Article

References (46)

1. Billingham M.E. Cardiac transplant atherosclerosis. Transplant Proc 19 (1987) 19-25
2. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
3. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
4. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
5. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
6. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335 (1996) 1001-1009
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 339 (1998) 1349-1357
8. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
9. Davingnon J., and Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10 (1999) 543-559
10. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., and Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 (1999) 178-184
11. Jaschke B., Michaelis C., Milz S., Vogeser M., Mund T., Hengst L., et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 68 (2005) 483-492
12. Hirozane T., Matsumori A., Furukawa Y., and Sasayama S. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation 91 (1995) 386-392
13. Saiura A., Sata M., Hiasa K., Kitamoto S., Washida M., Egashira K., et al. Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler Thromb Vasc Biol 24 (2004) 1886-1890
14. Corry R.J., Winn H.J., and Russell P.S. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16 (1973) 343-350
15. Koglin J., Glysing-Jensen T., Raisanen-Sokolowski A., and Russell M.E. Immune sources of transforming growth factor-beta1 reduce transplant arteriosclerosis: insight derived from a knockout mouse model. Circ Res 83 (1998) 652-660
16. Yamamoto T., Sata M., Fukuda D., and Takamoto S. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Res Cardiol 100 (2005) 84-91
17. Natori T., Sata M., Nagai R., and Makuuchi M. Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother 59 (2005) 56-60
18. Nabel E.G., Shum L., Pompili V.J., Yang Z.Y., San H., Shu H.B., et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A 90 (1993) 10759-10763
19. Waltenberger J., Akyurek M.L., Aurivillius M., Wanders A., Larsson E., Fellstrom B., et al. Ischemia-induced transplant arteriosclerosis in the rat. Induction of peptide growth factor expression. Arterioscler Thromb Vasc Biol 16 (1996) 1516-1523
20. Clark K.J., Cary N.R., Grace A.A., and Metcalfe J.C. Microsatellite mutation of type II transforming growth factor-beta receptor is rare in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 (2001) 555-559
21. Morrell N.W., Yang X., Upton P.D., Jourdan K.B., Morgan N., Sheares K.K., et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104 (2001) 790-795
22. Chorvat R.J., Desai B.N., Radak S.E., McLaughlin K.T., Miller J.E., Jett C., et al. 22-Hydroxycholesterol derivatives as HMG CoA reductase suppressors and serum cholesterol lowering agents. J Med Chem 28 (1985) 194-200
23. Davidson M.H. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 111 (2005) 2280-2281
24. Ross R. Genetically modified mice as models of transplant atherosclerosis. Nat Med 2 (1996) 527-528
25. Russell P.S., Chase C.M., Winn H.J., and Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 152 (1994) 5135-5141
26. Russell P.S., Chase C.M., Winn H.J., and Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol 144 (1994) 260-274
27. Hruban R.H., Beschorner W.B., Baumgartner W.A., Augustine S.M., Ren H., Reitz B.A., et al. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 137 (1990) 871-881
28. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
29. Allan J.S., Choo J.K., Vesga L., Arn J.S., Pins M.R., Sachs D.H., et al. Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy. Ann Thorac Surg 64 (1997) 1019-1025
30. Sata M., Luo Z., and Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 66 (2001) 6964-6971
31. Suzuki J.-I., Isobe M., Morishita R., Aoki M., Horie S., Okubo Y., et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 3 (1997) 900-903
32. Kawauchi M., Suzuki J., Morishita R., Wada Y., Izawa A., Tomita N., et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res. 87 (2000) 1063-1068
33. Meiser B.M., Billingham M.E., and Morris R.E. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 338 (1991) 1297-1298
34. Calne R.Y., Collier D.S.J., Lim S., Pollard S.G., Samaan A., White D.J.G., et al. Rapamycin for immunosuppression in organ allografting. Lancet 8656 (1989) 227
35. Sommer B.G., Innes J.T., Whitehurst R.M., Sharma H.M., and Ferguson R.M. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg 149 (1985) 759-764
36. Demetris A.J., Lasky S., Theil D.H., Starzl T.E., and Dekker A. Pathology of hepatic transplantation. A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid combination. Am J Pathol 118 (1985) 151-158
37. Bunchman T.E., and Brookshire C. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88 (1991) 310-314
38. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530-534
39. Corpataux J.M., Naik J., Porter K.E., and London N.J. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res 129 (2005) 52-56
40. Lagaaij E.L., Cramer-Knijnenburg G.F., van Kemenade F.J., van Es L.A., Bruijn J.A., and van Krieken J.H. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 357 (2001) 33-37
41. Simper D., Wang S., Deb A., Holmes D., McGregor C., Frantz R., et al. Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation 108 (2003) 143-149
42. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
43. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108 (2001) 391-397
44. Saiura A., Sata M., Hirata Y., Nagai R., and Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 7 (2001) 382-383
45. Shimizu K., Sugiyama S., Aikawa M., Fukumoto Y., Rabkin E., Libby P., et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 7 (2001) 738-741
46. Friedman T. Principles for human gene therapy studies. Science 287 (2000) 2163-2165